by Mike Masnick
Thu, Oct 7th 2010 10:34pm
Copycense points us to a NY Times piece about how pharmaceutical giant Eli Lilly is facing some tough times ahead. Why? Because the patents on the drugs that make up most of its revenue are all set to expire soon, and their pipeline of newly patented drugs is pretty far behind. Of course, what this highlights is the folly of relying on patents as your business model. The patents become a crutch, and you're unable to build a real business doing anything other than coming up with new patentable drugs. It takes the focus away from building a real business around making people healthy, to one that's focused on coming up with stuff we can sell that can be patented.
If you liked this post, you may also be interested in...
- Just As We Warned: A Chinese Tech Giant Goes On The Patent Attack -- In East Texas
- AstraZeneca Tries To Use 'Orphan Drug' Designation To Extend Patent Life Of Top-Selling Pill
- France Might Allow NGOs To Sell Public Domain Seeds To Non-Commercial Buyers. Might?
- Pharma Officials Insist That There Is 'Zero Evidence' That Patents Harm Access To Medicine
- Eli Lilly Enlists Congress In Fight Against Canada For Refusing Patent On Useless Drug